Policy
RFK peptides tracker: the six peptides in HHS's draft policy
Last checked: Nov 4, 2026. Educational only, not medical advice. PeptideX is not affiliated with any drug manufacturer.
Intro
In October 2026, HHS (led by Secretary Robert F. Kennedy Jr.) published a draft policy (proposed, not final) about how FDA would treat 503A pharmacy compounding with six peptides. Nothing in it is final yet. For the full explainer, see our HHS peptide draft policy guide.
Compounded drugs are not FDA-approved.
Tracker
| Peptide | Prior FDA category status | Status in the draft policy | Our page |
|---|---|---|---|
| BPC-157 | Previously Category 2; FDA's current list shows it as nominated but withdrawn | Named in Appendix A (proposed, not final) | /compounds/bpc-157 |
| Epitalon | Category 2 (Sept 2023 - Apr 22, 2026) | Named in Appendix A (proposed, not final) | /compounds/epitalon |
| KPV | Category 2 (Sept 2023 - Apr 22, 2026) | Named in Appendix A (proposed, not final) | /compounds/kpv |
| MOTS-c | Category 2 (Sept 2023 - Apr 22, 2026) | Named in Appendix A (proposed, not final) | /compounds/mots-c |
| Semax | Category 2 (Sept 2023 - Apr 22, 2026) | Named in Appendix A (proposed, not final) | /compounds/semax |
| TB-500 | Category 2 (Sept 2023 - Apr 22, 2026) | Named in Appendix A (proposed, not final) | /compounds/tb-500 |
What changes next: After Nov 13, HHS reviews comments; we'll update this tracker when a final policy posts.
Last checked: Nov 4, 2026. Sources: Federal Register 91 FR 68526 (FR Doc 2026-22192); HHS draft policy appendices (PDF); Docket HHS-OASH-2026-0496.
FAQ
What are the "RFK peptides"?
People use the phrase for the six peptides named in HHS's draft policy (proposed, not final): BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It's an informal nickname, not an official HHS term.
Is the draft policy final?
No. It is a draft policy (proposed, not final). HHS may change it after reviewing public comments.
When do public comments close?
The docket on regulations.gov lists Nov 13, 2026, 11:59 PM ET (HHS-OASH-2026-0496).
What was BPC-157's status before?
BPC-157 was previously Category 2; FDA's current list shows it as nominated but withdrawn.
Are compounded peptides FDA-approved?
No. Compounded drugs are not FDA-approved.
Where can I read more?
See our HHS peptide draft policy guide and each peptide's page in the table above.
Canonical: https://peptidex.ai/rfk-peptides